Clinical Cancer Research, Vol 4, Issue 3 635-642, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer

GT Budd, PC Adamson, M Gupta, P Homayoun, SK Sandstrom, RF Murphy, D McLain, L Tuason, D Peereboom, RM Bukowski and R Ganapathi
Department of Medical Oncology, The Cleveland Clinic Cancer Center, Ohio 44195, USA. buddg@cesmtp.ccf.org

Because tamoxifen and all-trans-retinoic acid (ATRA) have additive antitumor effects in preclinical systems, we performed a Phase I/II clinical trial of this combination in patients with advanced breast cancer. Patients with potentially hormone-responsive advanced breast cancer were enrolled. All received 20 mg of tamoxifen by mouth daily. Consecutive cohorts of 3-6 patients were treated on odd-numbered weeks with ATRA at doses of 70, 110, 150, 190, or 230 mg/m2/day. Twenty-six patients were entered in this trial; 25 were evaluable. A dose of 230 mg/m2 ATRA produced unacceptable headache and dermatological toxicity, but doses < or = 190 mg/m2 were tolerable. Two of 7 patients with measurable disease responded. Seven of 18 patients with evaluable, nonmeasurable disease achieved disease stability for more than 6 months. Plasma AUCs on day 1 of successive weeks of treatment were stable over time. A nonsignificant decrease in serum insulin-like growth factor I levels was noted during treatment, but this trend was similar to that observed in three "control" patients treated with tamoxifen alone. When given with daily tamoxifen, the maximum tolerated dose of ATRA that could be given on alternate weeks was 190 mg/m2/day. This schedule of ATRA resulted in repeated periods of exposure to potentially therapeutic concentrations of ATRA. Declines in the serum insulin-like growth factor I concentrations observed in patients treated with tamoxifen and ATRA were similar to those observed in patients treated with tamoxifen alone. Objective responses were observed, some in patients who had previously progressed while receiving tamoxifen, suggesting that further studies would be of interest.

This article has been cited by other articles:

				H. E. Cunliffe, M. Ringner, S. Bilke, R. L. Walker, J. M. Cheung, Y. Chen, and P. S. Meltzer The Gene Expression Response of Breast Cancer to Growth Regulators: Patterns and Correlation with Tumor Expression Profiles Cancer Res., November 1, 2003; 63(21): 7158 - 7166. [Abstract] [Full Text] [PDF]

				J. A. Lawrence, P. C. Adamson, R. Caruso, C. Chow, D. Kleiner, R. F. Murphy, D. J. Venzon, M. Shovlin, M. Noone, M. Merino, et al. Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations J. Clin. Oncol., May 15, 2001; 19(10): 2754 - 2763. [Abstract] [Full Text] [PDF]

				E. Sapi, M. B. Flick, K. Tartaro, S. Kim, Y. Rakhlin, S. Rodov, and B. M. Kacinski Effect of All-trans-Retinoic Acid on c-fms Proto-oncogene [Colony-stimulating Factor 1 (CSF-1) Receptor] Expression and CSF-1-induced Invasion and Anchorage-independent Growth of Human Breast Carcinoma Cells Cancer Res., November 1, 1999; 59(21): 5578 - 5585. [Abstract] [Full Text] [PDF]

				A. Radominska-Pandya, G. Chen, P. J. Czernik, J. M. Little, V. M. Samokyszyn, C. A. Carter, and G.{m. d.}y. Nowak Direct Interaction of All-trans-retinoic Acid with Protein Kinase C (PKC). IMPLICATIONS FOR PKC SIGNALING AND CANCER THERAPY J. Biol. Chem., July 14, 2000; 275(29): 22324 - 22330. [Abstract] [Full Text] [PDF]